Samsung Bioepis’ Remicade biosimilar set for CHMP verdict

pharmafile | March 31, 2016 | News story | Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab 

Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its Remicade (infliximab) biosimilar.

If green-lighted, Samsung Bioepis’ drug – named Flixabi – would be the second biosimilar version of Janssen and MSD’s original to hit the European market, following Celltrion’s.

It would also be Samsung Bioepis’ second biosimilar to be approved by EU regulators, following its Enbrel (etanercept) copy Benepali earlier this year.

The Korean firm is seeking approval for the Remicade biosimilar in all of the original’s indications: rheumatoid arthritis, adult and paediatric Crohn’s disease, ulcerative colitis, paediatric ulcerative colitis, psoriatic arthritis, ankylosing spondylitis and psoriasis.

The European Medicines Agency is expected to reveal the CHMP’s decision Friday, and a positive verdict will see the drug go to the European Commission for final approval.

UPDATE, 3/4/16, 16:35: The CHMP has recommended Flixabi for approval in the European Union

Joel Levy

Related Content


Samsung Bioepis & Biogen receive positive CHMP opinion for ranibizumab biosimilar

Samsung Bioepis and Biogen have announced that the EMA’s Committee for Medicinal Products for Human …

Biosimilars and Brexit: What’s in store for UK’s biosimilar market?

It’s been 15 years since the first biosimilar entered the market, and the impact of …


Celltrion’s infliximab biosimilar Remsima secures European approval in five indications

The subcutaneous (SC) formulation of Remsima, Celltrion’s biosimilar version of infliximab, has secured approval from …

Latest content